🔎 Trials Near Me

Home › Cancro del polmone non a piccole cellule › Virginia › Richmond

Studi clinici su Cancro del polmone non a piccole cellule a Richmond, VA

25 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Richmond e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.

Testo ufficiale dello studio (inglese)

Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

In reclutamentoFase 3
  • Virginia Cancer Institute, Richmond
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

In reclutamentoFase 3
  • VCU Health Adult Outpatient Pavillion ( Site 0193), Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06623422

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

In reclutamentoFase 3
  • Virginia Cancer Institute, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06498635

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

In reclutamentoFase 3
  • Local Institution - 0337, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07361510

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

In reclutamentoFase 3
  • VCU Medical Center Gateway Building, Richmond
  • Virginia Commonwealth University, Richmond
  • VCU Health Short Pump Pavilion, Richmond
  • e altri 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07144280

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

In reclutamentoFase 1/2
  • VCU Medical Center Gateway Building, Richmond
  • Virginia Commonwealth University, Richmond
  • VCU Health Stony Point, Richmond
  • e altri 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07227298

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

In reclutamentoFase 3
  • VCU Health Adult Outpatient Pavillion, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06890598

Pan-tumor MRD Study

In reclutamentoStudio osservazionale
  • Virginia Cancer Institute, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06605404

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

In reclutamentoFase 3
  • Research Site, Richmond
  • Research Site, Midlothian · a 11 mi di distanza
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06357533

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

In reclutamentoFase 2/3
  • VCU Massey Cancer Center, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06712316

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

In reclutamentoFase 2/3
  • Virginia Commonwealth University (Vcu), Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07100080

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

In reclutamentoFase 3
  • Clinical Study Site, Richmond
  • Clinical Study Site, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

In reclutamentoFase 2/3
  • Virginia Cancer Institute - West End, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT04613596

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

In reclutamentoFase 3
  • VCU Health Adult Outpatient Pavillion, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

In reclutamentoFase 3
  • Research Site, Midlothian · a 11 mi di distanza
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT06350097

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

In reclutamentoFase 3
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 lug 2026 · NCT06686771

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

In reclutamentoFase 2
  • VCU Medical Center (Virginia Commonwealth University), Richmond
Età da 18 a 70 · Tutti i sessi · Aggiornato il 26 giu 2026 · NCT04614103

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

In reclutamentoFase 2
  • Virginia Commonwealth University, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 giu 2026 · NCT06731413

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

In reclutamentoFase 2
  • Virginia Cancer Institute, Richmond
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT06116682

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

In reclutamentoFase 2
  • Virginia Commonwealth University, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04317534

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

In reclutamentoFase 2/3
  • Virginia Cancer Institute, Richmond
  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06616584

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

In reclutamentoFase 2
  • Virginia Commonwealth University, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 apr 2026 · NCT06248606

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

In reclutamentoStudio osservazionale
  • VCU Massey Cancer Center at Stony Point, Richmond
  • Virginia Commonwealth University/Massey Cancer Center, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06418204

Repositioning Immunotherapy in VetArans With Lung Cancer

In reclutamentoFase 2
  • Richmond VA Medical Center, Richmond, VA, Richmond
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06275360

Studi su Cancro del polmone non a piccole cellule in altre città

Altri studi a Richmond

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.